ARVN

SEC source: 0001209191-20-020803 · doc4.xml · derivative · entry 4

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,384

Underlying: Common Stock · 758 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 1, 2019, with the remainder of the shares vesting in equal monthly installments following January 1, 2019 through January 1, 2022.

SEC source: 0001209191-20-020803 · doc4.xml · derivative · entry 3

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,191

Underlying: Common Stock · 1,139 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of June 28, 2019, with the remainder of the shares vesting in equal monthly installments following June 28, 2019 through June 28, 2022.

SEC source: 0001209191-20-020803 · doc4.xml · derivative · entry 2

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,815

Underlying: Common Stock · 6,133 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 1, 2017, with the remainder of the shares vesting in equal monthly installments following January 1, 2017 through January 1, 2020.

SEC source: 0001209191-20-020803 · doc4.xml · nonDerivative · entry 1

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,422

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-021041 · doc4.xml · derivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 88,150

Underlying: Common Stock · 6,250 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 5, 2018, with the remainder of the shares vesting in equal monthly installments following January 5, 2018 through January 5, 2021.

SEC source: 0001209191-20-021041 · doc4.xml · nonDerivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 816,200

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-020734 · doc4.xml · nonDerivative · entry 1

SHANNON TIMOTHY M · CIK 0001207114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,623

F1 · balance_after: Includes shares received by the Reporting Person in a prior distribution.

SEC source: 0001209191-20-020799 · doc4.xml · derivative · entry 3

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,056

Underlying: Common Stock · 2,686 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 10,742 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 10,742 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

SEC source: 0001209191-20-020799 · doc4.xml · nonDerivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,398

F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.

F3 · price: The broker sold shares of Arvinas Common Stock for certain Arvinas employees following the vesting of previously granted Restricted Stock Units, including the Common Stock reported on this Form 4 by the Reporting Person, at an average price of $37.61.

SEC source: 0001209191-20-020799 · doc4.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,224

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-20-020795 · doc4.xml · derivative · entry 3

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,374

Underlying: Common Stock · 4,791 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 19,165 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 19,165 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

SEC source: 0001209191-20-020795 · doc4.xml · nonDerivative · entry 2

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,392

F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.

F3 · price: The broker sold shares of Arvinas Common Stock for certain Arvinas employees following the vesting of previously granted Restricted Stock Units, including the Common Stock reported on this Form 4 by the Reporting Person, at an average price of $37.61.

SEC source: 0001209191-20-020795 · doc4.xml · nonDerivative · entry 1

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,906

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-20-020801 · doc4.xml · derivative · entry 3

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,531

Underlying: Common Stock · 17,511 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

F4 · derivative.exercise_date: On March 1, 2019, the reporting person was granted 70,042 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

F4 · derivative.expiration_date: On March 1, 2019, the reporting person was granted 70,042 Restricted Stock Units, vesting in four equal annual installments beginning March 1, 2020.

SEC source: 0001209191-20-020801 · doc4.xml · nonDerivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 809,950

F2 · shares: This sale was made to cover withholding taxes following the vesting of previously granted Restricted Stock Units.

F3 · price: The broker sold shares of Arvinas Common Stock for certain Arvinas employees following the vesting of previously granted Restricted Stock Units, including the Common Stock reported on this Form 4 by the Reporting Person, at an average price of $37.61.

SEC source: 0001209191-20-020801 · doc4.xml · nonDerivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 815,355

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0001209191-20-020503 · doc4.xml · nonDerivative · entry 1

Margus Bradley Albert · CIK 0001753491 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,463

SEC source: 0001209191-20-020729 · doc4a.xml · nonDerivative · entry 1

Margus Bradley Albert · CIK 0001753491 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,463

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F2 · price: This amendment is being filed to clarify that the shares reported on the reporting person's Form 4 filed on March 20, 2020 were sold at a range of transaction prices, and to report the number of shares of Common Stock indirectly held by the reporting person in Table 1.

SEC source: 0001209191-20-014636 · doc4.xml · derivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2030-02-26

F1 · derivative.exercise_date: This option award was granted on February 27, 2020. 1/4 of the shares underlying the award shall vest on February 27, 2021, with the remainder of the shares vesting in equal monthly installments following February 27, 2021 through February 27, 2024.

SEC source: 0001209191-20-014640 · doc4.xml · derivative · entry 1

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2030-02-26

F1 · derivative.exercise_date: This option award was granted on February 27, 2020. 1/4 of the shares underlying the award shall vest on February 27, 2021, with the remainder of the shares vesting in equal monthly installments following February 27, 2021 through February 27, 2024.

SEC source: 0001209191-20-014684 · doc4.xml · derivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 235,000

Underlying: Common Stock · 235,000 shares

Expires 2030-02-26

F1 · derivative.exercise_date: This option award was granted on February 27, 2020. 1/4 of the shares underlying the award shall vest on February 27, 2021, with the remainder of the shares vesting in equal monthly installments following February 27, 2021 through February 27, 2024.

SEC source: 0001209191-20-014678 · doc4.xml · derivative · entry 1

Peck Ronald · CIK 0001783868 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2030-02-26

F1 · derivative.exercise_date: This option award was granted on February 27, 2020. 1/4 of the shares underlying the award shall vest on February 27, 2021, with the remainder of the shares vesting in equal monthly installments following February 27, 2021 through February 27, 2024.

SEC source: 0001209191-20-008425 · doc4.xml · nonDerivative · entry 5

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,115

F1 · kind: The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019.

SEC source: 0001209191-20-008425 · doc4.xml · nonDerivative · entry 4

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,145

F1 · kind: The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.79 to $53.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-20-008425 · doc4.xml · nonDerivative · entry 3

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,447

F1 · kind: The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.73 to $52.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-20-008425 · doc4.xml · nonDerivative · entry 2

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,327

F1 · kind: The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.48 to $51.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range

SEC source: 0001209191-20-008425 · doc4.xml · nonDerivative · entry 1

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 154,517

F1 · kind: The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on December 20, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.41 to $50.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-20-005638 · doc4.xml · derivative · entry 3

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,648

Underlying: Common Stock · 11,742 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option award was granted on September 26, 2018, 1/4 of the shares underlying the award vested as of June 1, 2017, with the remainder of the shares vesting in equal monthly installments following June 1, 2017 through June 1, 2020.

SEC source: 0001209191-20-005638 · doc4.xml · derivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

Underlying: Common Stock · 1,300 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018, 1/4 of the shares underlying the award vested as of January 1, 2019, with the remainder of the shares vesting in equal monthly installments following January 1, 2019 through January 1, 2022.

SEC source: 0001209191-20-005638 · doc4.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,538

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-061326 · doc4.xml · derivative · entry 2

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,400

Underlying: Common Stock · 12,500 shares

Expires 2028-09-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option award was granted on September 26, 2018. 1/4 of the shares underlying the award vested as of January 5, 2018, with the remainder of the shares vesting in equal monthly installments following January 5, 2018 through January 5, 2021.

SEC source: 0001209191-19-061326 · doc4.xml · nonDerivative · entry 1

Houston John G · CIK 0001753537 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 797,844

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-19-057808 · doc4.xml · derivative · entry 1

Smaldone Alsup Laurie · CIK 0001589602 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,846

Underlying: Common Stock · 25,846 shares

Expires 2029-11-19

F1 · derivative.exercise_date: This option award was granted on November 20, 2019. The shares underlying the award shall vest in equal monthly installments through November 20, 2022.

SEC source: 0001209191-19-057640 · doc4.xml · nonDerivative · entry 1

Cassidy Sean A · CIK 0001421914 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,115

F1 · kind: The sales reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 27, 2019.

SEC source: 0001209191-19-056788 · doc4.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,496

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2019.

SEC source: 0000899243-19-027280 · doc4.xml · nonDerivative · entry 1

Ratcliffe Liam · CIK 0001547100 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 680,000

F1 · ownership.nature: The reported shares are held directly by AI Biotechnology LLC ("AIB"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.

SEC source: 0001209191-19-055696 · doc4.xml · nonDerivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,496

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.04 to $24.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-19-055696 · doc4.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,496

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.03 to $24.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-19-051780 · doc4.xml · nonDerivative · entry 2

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,496

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.39 to $22.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001209191-19-051780 · doc4.xml · nonDerivative · entry 1

Taylor Ian · CIK 0001753281 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,796

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 29, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.36 to $22.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

SEC source: 0001104659-19-051601 · a4.xml · nonDerivative · entry 1

PARMAR KUSH · CIK 0001664281 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,775

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 8

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,002

F16 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Co-Investor III to Dr. John D. Diekman.

F17 · ownership.nature: These securities are held of record by Dr. John D. Diekman and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 7

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 8,540

F14 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to MADRock II LLC ("MADRock II").

F15 · ownership.nature: These securities are held of record by MADRock II. Dr. Rocklage is a manager of MADRock II and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 6

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 8,540

F12 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to Scott M. Rocklage Revocable Trust dated 10/22/15; Trustees: Scott M. Rocklage and Patty B. Rocklage ("Rocklage Trust").

F13 · ownership.nature: These securities are held of record by Rocklage Trust. Dr. Rocklage is a trustee and beneficiary of the Rocklage Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 5

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 17,079

F10 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to the Schwab Family Trust, Andrew J. Schwab and Catarina N. Schwab, as Trustees of the Schwab Family Trust, dated October 26, 2007 ("Schwab Family Trust").

F11 · ownership.nature: These securities are held of record by Schwab Family Trust. Mr. Schwab is a trustee and beneficiary of the Schwab Family Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 4

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 17,079

F8 · kind: Represents the receipt of shares of Common Stock of the Issuer by virtue of the pro-rata in-kind distribution by Partners III to John D. Diekman and Susan P. Diekman Trustees Diekman Revocable Trust Dtd 6/30/95 ("Diekman Trust").

F9 · ownership.nature: These securities are held of record by Diekman Trust. Dr. Diekman is a trustee and beneficiary of the Diekman Trust and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 3

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 85,396

F5 · kind: Represents a change in the form of ownership of 5AM Partners III, LLC ("Partners III") by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by Ventures III and Co-Investors III.

F6 · ownership.nature: These Securities are held of record by Partners III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Partners III. Each of Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of his pecuniary interest therein.

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 2

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 79,856

F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by 5AM Co-Investors III, L.P. ("Co-Investors III") without consideration to its partners.

F4 · ownership.nature: These Securities are held of record by Co-Investors III.

F7 · ownership.nature: Partners III is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

SEC source: 0001104659-19-050625 · a4.xml · nonDerivative · entry 1

5AM VENTURES III, L.P. · CIK 0001456890 · 10% owner

5AM Partners III, LLC · CIK 0001555953 · 10% owner

5AM Co-Investors III, L.P. · CIK 0001478660 · 10% owner

DIEKMAN JOHN D · CIK 0001240357 · 10% owner

ROCKLAGE SCOTT M · CIK 0001219014 · 10% owner

Schwab Andrew J. · CIK 0001598549 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 3,098,567

F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by 5AM Ventures III, L.P. ("Ventures III") without consideration to its partners.

F2 · ownership.nature: These Securities are held of record by Ventures III.

F7 · ownership.nature: Partners III is the sole general partner of Ventures III and Co-Investors III. Dr. John D. Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage are the managing members of Partners III, and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures III and Co-Investors III. Each of Partners III, Dr. Diekman, Mr. Schwab and Dr. Rocklage disclaim beneficial ownership of such shares except to the extent of its or his pecuniary interest therein.

SEC source: 0001104659-19-050626 · a4.xml · nonDerivative · entry 1

PARMAR KUSH · CIK 0001664281 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,475

F1 · kind: Represents a receipt of shares of Common Stock of the Issuer by virtue of a pro-rata in-kind distribution by 5AM Partners III, LLC to its members.